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Abstract: There is a tremendous need for developing new useful prognostic factors in ovarian cancer.
Galectins are a family of carbohydrate binding proteins which have been suggested to serve as
prognostic factors for various cancer types. In this study, the presence of Galectin-1, -3, and -7 was
investigated in 156 ovarian cancer specimens by immunochemical staining. Staining was evaluated in
the cytoplasm and nucleus of cancer cells as well as the peritumoral stroma using a semi quantitative
score (Remmele (IR) score). Patients’ overall survival was compared between different groups of
Galectin expression. Galectin (Gal)-1 and -3 staining was observed in the peritumoral stroma as
well as the nucleus and cytoplasm of tumor cells, while Gal-7 was only present in the cytoplasm
of tumor cells. Patients with Gal-1 expression in the cytoplasm or high Gal-1 expression in the
peritumoral stroma showed reduced overall survival. Nuclear Gal-3 staining correlated with a better
outcome. We observed a significantly reduced overall survival for cases with high Gal-7 expression
and a better survival for Gal-7 negative cases, when compared to cases with low expression of Gal-7.
We were able to show that both tumor and stroma staining of Gal-1 could serve as negative prognostic
factors for ovarian cancer. We were able to confirm cytoplasmic Gal-7 as a negative prognostic factor.
Gal-3 staining in the nucleus could be a new positive prognosticator for ovarian cancer.
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1. Introduction
Ovarian cancer is the most lethal gynecological malignancy, ranking fifth in estimated cancer
deaths among women in the USA [1]. First-line treatment consists of primary debulking surgery
followed by platinum and paclitaxel chemotherapy [2]. Still, the 5-year relative survival rate for
epithelial ovarian cancer patients is less than 50% [3]. A lack of screening methods and the frequent
presentation with advanced stage disease are considered as the main reasons for the poor outcome
of ovarian cancer patients. Disease stage at diagnosis, extent of residual disease after surgery,
histological subtype, and a high volume of ascites can be used as prognosticators in ovarian cancer [4].
Numerous studies have aimed to introduce new biological prognostic factors in ovarian cancer.
Recently, carbohydrate stem cell marker TF1 has been proposed as negative prognostic marker in
ovarian cancer displaying wildtype p53, while estrogen receptor promoter methylation could predict
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overall survival in low-grade ovarian carcinoma patients [5,6]. Although for these and various other
molecules the prognostic value independently of clinical parameters has been proven, until today,
except for breast cancer gene (BRCA)-status, no biological marker is commonly accepted [4]. Further
specification of anti-cancer therapy necessarily requires an improvement of biological prognostic
markers in ovarian cancer.
Galectins have been defined as a family of proteins sharing two main characteristics: a binding
affinity for β-galactosides and a significant similarity in the carbohydrate-recognition domain (CRD) [7].
The first member of this family described was Galectin-1, which is isolated as homodimers composed of
two identical CRD subunits [8]. Since then, the Galectin family has had a growing number of members,
but only Galectin (Gal)-1–4, Gal-7–10, Gal-12, and Gal-13 are known to be present in humans [9].
Similar to Gal-1, Gal-7 typically occurs in homodimers, while Gal-3 is the only Galectin characterized
chimeric protein known to form higher order oligomers [10,11]. In several cancer types, Galectins are
known to affect tumor growth, metastasis, angiogenesis, cell migration, as well as tumor invasiveness
and progression, and are therefore very likely to show a prognostic value for patients’ survival [9,12].
The role of Galectin-1 in cancer has been studied by various groups, and several papers already
exist on this topic. For patients’ sera and ovarian cancer tissue, it has been shown that a combination
of CA-125 and Galectin-1 serves as a possible two-marker combination for preoperative discrimination
of benign and malignant ovarian masses [13]. Also, patients suffering from metastatic epithelial
ovarian cancer were observed to show higher serum Gal-1 levels than those with non- metastatic type.
Elevated peritumoral stroma staining of Gal-1 was shown to occur in advanced stages of epithelial
ovarian cancer and is also connected with poorer progression-free survival in univariate analysis [14].
However, these results have not yet been reproduced for overall survival or confirmed by multivariate
analysis [15]. Due to this, the possibility of Gal-1 as an independent prognostic marker in ovarian
cancer still needs to be further investigated.
High cytoplasmic Galectin-3 expression has been suggested as a negative prognostic factor, as
it was shown to correlate with shorter progression-free survival in ovarian cancer [16]. However,
in another study, Gal-3 expression did not correlate to reduced overall survival, but a cytoplasmic
staining pattern was associated with poor outcome when compared to patterns including nuclear
staining [17]. Although Gal-3 staining in nucleus and stroma has been observed, their influence on
overall survival still maintains elusive. Galectin-7 has been proposed to serve as negative prognostic
factor in ovarian cancer by two independent groups. In both studies, its influence on progression-free
survival and overall survival has been confirmed by univariate and multivariate analysis [16,18]. Yet,
there is further disagreement whether Gal-7 staining occurs predominantly in the nucleus or the
cytoplasm. Also, it remains unknown if there is a correlation between expressions of different Galectins
in ovarian cancer, and there is a desperate need for comprehensive studies of various Galectins on a
representative ovarian cancer panel. Therefore, in this study, we investigated the prognostic influence
of Gal-1, -3, and -7 in patients with epithelial ovarian cancer and analyzed correlations to each other
and to clinical and pathological parameters. We hypothesize that Gal-1, -3, and -7 are prognostic for
overall survival in ovarian cancer patients, dependent of the localization of the Galectin expression.
2. Results
2.1. Gal-1 Tumor and Stroma Staining Is Negative Prognostic for Overall Survival
Galectin-1 staining was successfully performed on 150 ovarian cancer specimens. Gal-1 was
present in the cytoplasm and the nuclei of ovarian cancer cells, as well as the peritumoral stroma
(Figure 1). In 102 cases (68.0%), the cytoplasms of tumor cells were positive for Gal-1, with a median
Remmele score (IRS) of 3. Peritumoral stroma was positive for Gal-1 in 148 cases (98.0%), with a
median IRS of 8. Gal-1 expression significantly correlated with several clinical and pathological data
(Table 1).
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Figure 1. Detection of Galectins by immunohistochemistry. Representative photomicrographs are 
shown. Galectin (Gal)-1 was present in the cytoplasm and the nuclei of ovarian cancer cells (A) as 
well as the peritumoral stroma (B); Gal-3 staining was observed in the nuclei, cytoplasm (C), and 
stroma (D); Staining for Galectin-7 was mainly observed in the cytoplasm (E); only a few individual 
cases showed nuclear staining (F); 10× magnification was used for the outer pictures and 50× 
magnification for the inserts. The scale bars in in the outer pictures equal 200 μm (10× magnification) 
and the scale bars in the inserts equal 100 μm (50× magnification). 
Table 1. Gal-1 staining correlated with clinical and pathological data. 
Clinical and  
Pathological  
Variables 
Gal-1 Expression 
Cytoplasm p 
Gal-1 
Expression 
Stroma 
p 
Gal-1 Expression  
Nucleus p 
 negative positive  low high  negative positive  
Histology          
Serous 26 79 0.008 34 71 NS 27 78 0.002 
Clear cell 5 7  6 6  3 9  
Endometrioid 8 12  7 13  11 9  
Mucinous 9 4  3 10  9 4  
Tumor Stage          
pT1 22 17 <0.001 20 19 0.006 19 20 0.020 
pT2+ 26 84  30 80  31 79  
Lymph node          
pN0/pNX 36 65 NS 34 67 NS 43 58 0.001 
pN1 12 37  16 33  7 42  
Distant Metastasis          
pM0/pMX 47 97 NS 49 95 NS 49 95 NS 
pM1 1 5  1 5  1 5  
Grading          
G1 20 16 <0.001 13 23 NS 14 22 NS 
G2+ 22 80  31 71  31 71  
FIGO          
I/II 22 21 0.001 17 26 NS 21 22 0.013 
III/IV 24 78  31 71  28 74  
Age          
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Figure 1. Detection of Galectins by immunohistochemistry. Representative photomicrographs are
shown. Galectin (Gal)-1 was present in the cytoplas and the nuclei of ovarian cancer cells (A) as well
as the peritumoral stroma (B); Gal-3 staining was observed in the nuclei, cytoplasm (C), and stroma
(D); Staining for Galectin-7 was mainly observed in the cytoplasm (E); only a few indivi ual cases
showed nuclear staining (F); 10× magnificatio w s used for the outer pictures and 50× mag ification
for the inserts. The scal bars in in the outer pictures equal 200 µm (10×magnification) a d the scale
bars in the inserts equal 100 µm (50×magnification).
Table 1. Gal-1 staining correlated with clinical and pathological data.
Clinical and
Pathological Variables
Gal-1 Expression
Cytoplasm p
Gal-1 Expression
Stroma p
Gal-1 Expression
Nucleus p
negative positive low high negative positive
Histology
Serous 26 79 0.008 34 71 NS 27 78 0.002
Clear cell 5 7 6 6 3 9
Endometrioid 8 12 7 13 11 9
Mucinous 9 4 3 10 9 4
Tumor Stage
pT1 22 17 <0.001 20 19 0.006 19 20 0.020
pT2+ 26 84 30 80 31 79
Lymph node
pN0/pNX 36 65 NS 34 67 NS 43 58 0.001
pN1 12 37 16 33 7 42
Dist nt Metastasis
pM0/pMX 47 97 NS 49 95 NS 49 95 NS
pM1 1 5 1 5 1 5
Grading
G1 20 16 <0.001 13 23 NS 14 22 NS
G2+ 22 80 31 71 31 71
FIGO
I/II 22 21 0.001 17 26 NS 21 22 0.013
III/IV 24 78 31 71 28 74
Age
≤60 years 27 52 NS 28 51 NS 24 55 NS
≤60 years 21 50 22 49 26 45
TNM staging was accomplished according to actual standards of Union for International Cancer Control (UICC);
pT1 = tumor stage 1; pT2+ = tumor stage 2 or higher; pN0 = lymph node stage 0; pNX = lymph node stage not
ev luated; pN1 = lymph node stage 1; pM0 = distant metastasis stage 0; pMX = distant metastasis not evaluated;
pM1 = distant metastasis stage 1; G1 = grade 1; G2+ = grade 2 or higher; FIGO = Fédération Internationale de
Gynécologie et d’Obstétrique; NS = Not significant (p > 0.05).
Gal-1 staining in cytoplasm and nucleus showed differences for several histological subtypes
(p = 0.008, p = 0.002, respectively). Cytoplasmic Gal-1 staining was significantly stronger in serous,
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clear cell, or endometrioid subtypes, while for mucinous subtype we found more negative cases.
Also, more cases showed Gal-1 positive nuclei for serous and clear cell subtypes, while endometrioid
and mucinous subtypes had weaker nuclear Gal-1 stainings. Furthermore, Gal-1 staining in nucleus,
cytoplasm, and stroma were significantly higher in cases with advanced tumor stage (p < 0.001,
p = 0.006, p = 0.02, respectively). Gal-1 expression in the cytoplasm was significantly higher in cases
with higher grading (p < 0.001) and advanced FIGO (Fédération Internationale de Gynécologie et
d’Obstétrique) stage (p = 0.001). Gal-1 staining in the nucleus showed higher IR scores in lymph node
positive cases (p = 0.001) and cases with advanced FIGO stage (p = 0.013).
Survival times of different groups of Gal-1 expression in nucleus, cytoplasm, and stroma have
been compared (Figure 2). Cases with Gal-1 expression in the cytoplasm showed significantly reduced
overall survival compared to cases without any Gal-1 expression in the cytoplasm (p = 0.029) Moreover,
cases displaying high Gal-1 expression in the stroma showed a significantly reduced outcome compared
to cases with low Gal-1 expression in the stroma (p = 0.045). Comparing negative versus positive
cases of Gal-1 expression in the nucleus did not show any differences with regard to overall survival.
However, based on considering a multivariate analysis, only Gal-1 stroma staining would serve as an
independent prognostic factor (Table 2).
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Figure 2. Survival times were plotted as Kaplan-Meier graphs. Percentage of living patients (vertical
axis) was plotted in dependence of time (horizontal axis). Patients without an observed event (death)
who exited the study before the observat on pe iod end d hav been censored. Censoring has
been marked in the graphs. Survival times of different groups of Galectin expression have been
compared. Cases displaying high Gal-1 expression in the stroma showed a significantly reduced
outcome compared to cases with low Gal-1 expression in the stroma. (A) Cases with Gal-1 expression
in the cytoplasm showed significantly reduced overall survival compared to cases without any Gal-1
expression in cytoplasm; (B) Cases without Gal-3 ex sion in nuclei showed ig ificantly reduced
overall survival compared to cases with nuclear Gal-3 expression; (C) Cases with high Gal-7 expression
showed a significantly reduced overall survival and Gal-7 negative cases showed better overall survival,
when compared to cases with low expression of Gal-7; (D) Galectin expression was determined in
cytoplasm, nucleus, and stroma using Remmele (IR) scores.
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Table 2. Multivariate analysis.
Covariate Coefficient (bi) HR Exp (bi)
95% CI
p-Value
Lower Upper
Histology (serous vs. other) 0.211 1.235 0.658 2.317 0.511
Grade (G1 vs. G2, G3) 0.942 2.565 1.290 5.100 0.007
FIGO (I, II vs. III, IV) 1.140 3.126 1.537 6.357 0.002
Patients’ age (≤60 vs. >60 years) 0.312 1.367 0.861 2.169 0.185
Gal-1 stroma (low vs. high) 0.571 1.770 1.044 2.999 0.034
Gal-1 cytoplasm (neg. vs. pos.) −0.187 0.830 0.423 1.626 0.586
Gal-3 nucleus (neg. vs. pos.) −0.265 0.767 0.480 1.227 0.269
Gal-7 cytoplasm (neg. vs. pos.) 0.636 1.889 1.160 3.077 0.011
HR = hazard ratio; CI = confidence interval.
2.2. Presence of Gal-3 in Nuclei Is A Positive Prognosticator in Ovarian Cancer
Gal-3 positive nuclei were observed in 83 (55%) out of 151 cases, while 96 cases (63.6%) showed
cytoplasmic Gal-3 staining and 85 cases (56.3%) presented with Gal-3 positive peritumoral stroma
(Figure 1). Median IR scores for Gal-3 in nuclei, cytoplasm, and stroma were 1, 2, and 1, respectively.
Gal-3 staining showed correlations with clinical and pathological data (Table 3). Gal-3 expression in
stroma and nucleus was different for several histological subtypes (p = 0.008, p = 0.013, respectively).
Gal-3 stroma staining was stronger in serous and clear cell subtypes but weaker in endometrioid and
mucinous subtypes, while nuclear Gal-3 staining was stronger in serous, clear cell, and mucinous
subtypes but weaker in endometrioid subtype. Tumors rated as pT1 presented with significantly
stronger nuclear Gal-3 staining than pT2 or higher staged cases (p = 0.042). We observed a correlation
of Gal-3 in nucleus and cytoplasm with patients′ age (p = 0.022, p = 0.013, respectively), with higher
IR scores for patients younger than 60 years. For our study panel, Gal-3 overexpression in the
cytoplasm was not correlated with poorer outcome of ovarian cancer patients. Also, Gal-3 staining
in the peritumoral stroma could not serve as a prognostic factor. However, nuclear Gal-3 expression
could serve as a positive prognostic factor (Figure 2). Cases without Gal-3 expression in nuclei showed
significantly reduced overall survival compared to cases with nuclear Gal-3 expression (p = 0.034).
According to the results of a multivariate analysis, nuclear Gal-3 staining could not serve as an
independent prognostic factor, probably due to its strong correlations with patients’ age, tumor stage,
and histology (Table 2).
Table 3. Gal-3 staining correlated with clinical and pathological data.
Clinical and
Pathological Variables
Gal-3 Expression
Cytoplasm p
Gal-3 Expression
Stroma p
Gal-3 Expression
Nucleus p
neg. pos. neg. pos. neg. pos.
Histology
Serous 37 69 NS 42 64 0.008 44 62 0.013
Clear cell 3 9 2 10 3 9
Endometrioid 12 9 13 8 16 5
Mucinous 3 9 9 3 5 7
Tumor Stage
pT1 12 27 NS 21 18 NS 12 27 0.042
pT2+ 43 68 44 67 55 56
Lymph node
pN0/pNX 39 62 NS 47 54 NS 48 53 NS
pN1 16 34 19 31 20 30
Distant Metastasis
pM0/pMX 53 92 NS 64 81 NS 65 80 NS
pM1 2 4 2 4 3 3
Grading
G1 9 28 NS 16 21 NS 13 24 NS
G2+ 40 62 44 58 51 51
FIGO
I/II 13 30 NS 21 22 NS 15 28 NS
III/IV 41 62 43 60 51 52
Age
≤60 years 22 57 0.022 33 46 NS 28 51 0.013
>60 years 33 39 33 39 40 32
TNM staging was accomplished according to actual standards of UICC; pT1 = tumor stage 1; pT2+ = tumor
stage 2 or higher; pN0 = lymph node stage 0; pNX = lymph node stage not evaluated; pN1 = lymph node stage
1; pM0 = distant metastasis stage 0; pMX = distant metastasis not evaluated; pM1 = distant metastasis stage 1;
G1 = grade 1; G2+ = grade 2 or higher; NS = Not significant (p > 0.05).
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2.3. Gal-7 Expression Level Predicts Shortened Overall Survival in Ovarian Cancer
Staining for Galecin-7 was mainly observed in the cytoplasm; only few individual cases showed
nuclear staining (Figure 1). Cytoplasmic Gal-7 staining was present in 129 (86.6%) out of 149 specimens,
with a median IR score of 3. In total, 20 cases presented negative for Gal-7, while 114 cases showed
low and 15 cases showed high expression of Gal-7. Gal-7 expression appeared to show differences for
several histological subtypes (p = 0.026). The strongest Gal-7 staining was found in serous subtype, and
the weakest was in endometrioid subtype (Table 4). No other correlation of Gal-7 with pathological
data was found. Survival times of Gal-7 negative cases and cases displaying a high Gal-7 expression
were compared to cases with low Gal-7 expression (Figure 2). We observed a significantly reduced
overall survival for cases with high Gal-7 expression and a better survival for Gal-7 negative cases,
when compared to cases with low expression of Gal-7 (p = 0.014). Also, according to the results of a
multivariate analysis, higher Gal-7 expression can be confirmed as an independent prognostic factor
for overall survival in ovarian cancer (Table 2).
Table 4. Gal-7 staining correlated with clinical and pathological data.
Clinical and Pathological Variables Gal-7 Expression Cytoplasm p
neg. low high
Histology
Serous 10 83 12 0.026
Clear cell 0 10 2
Endometrioid 7 13 0
Mucinous 3 8 1
Tumor Stage
pT1 4 29 5 NS
pT2+ 15 85 10
Lymph node
pN0/pNX 15 75 8 NS
pN1 5 39 7
Distant Metastasis
pM0/pMX 19 110 14 NS
pM1 1 4 1
Grading
G1 6 25 3 NS
G2+ 12 80 11
FIGO
I/II 8 29 4 NS
III/IV 11 81 11
Age
≤60 years 12 59 8 NS
>60 years 8 55 7
TNM staging was accomplished according to actual standards of UICC; pT1 = tumor stage 1; pT2+ = tumor
stage 2 or higher; pN0 = lymph node stage 0; pNX = lymph node stage not evaluated; pN1 = lymph node stage
1; pM0 = distant metastasis stage 0; pMX = distant metastasis not evaluated; pM1 = distant metastasis stage 1;
G1 = grade 1; G2+ = grade 2 or higher; NS = Not significant (p > 0.05).
2.4. Correlation Analysis
A correlation analysis is shown in Table 5. For Gal-1 staining, we observed positive correlations
between staining in cytoplasm, nucleus, and stroma. Also, staining results of Gal-3 in cytoplasm,
nucleus, and stroma were positively correlated among each other. Furthermore, we found correlations
between Galectin-1 and -3 staining in nucleus, cytoplasm, and stroma. Gal-7 staining showed positive
correlations with Gal-1 in cytoplasm and nucleus and all types of Gal-3 staining.
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Table 5. Correlation analysis.
Staining Gal-1Cytoplasm
Gal-1
Stroma
Gal-1
Nucleus
Gal-3
Cytoplasm
Gal-3
Stroma
Gal-3
Nucleus
Gal-7
Cytoplasm
Gal-1 cytoplasm
cc 1.000 0.382 0.748 0.356 0.263 0.282 0.272
p . <0.001 <0.001 <0.001 0.001 <0.001 0.001
n 150 150 150 149 149 149 146
Gal-1 stroma
cc 0.382 1.000 0.231 0.123 0.280 −0.006 −0.040
p <0.001 . 0.004 0.135 0.001 0.937 0.633
n 150 150 150 149 149 149 146
Gal-1 nucleus
cc 0.748 0.231 1.000 0.302 0.315 0.329 0.249
p <0.001 0.004 . <0.001 <0.001 <0.001 0.002
n 150 150 150 149 149 149 146
Gal-3 cytoplasm
cc 0.356 0.123 0.302 1.000 0.293 0.839 0.276
p <0.001 0.135 <0.001 . <0.001 <0.001 0.001
n 149 149 149 151 151 151 146
Gal-3 stroma
cc 0.263 0.280 0.315 0.293 1.000 0.267 0.231
p 0.001 0.001 <0.001 <0.001 . 0.001 0.005
n 149 149 149 151 151 151 146
Gal-3 nucleus
cc 0.282 −0.006 0.329 0.839 0.267 1.000 0.335
p <0.001 0.937 <0.001 <0.001 0.001 . <0.001
n 149 149 149 151 151 151 146
Gal-7 cytoplasm
cc 0.272 −0.040 0.249 0.276 0.231 0.335 1.000
p 0.001 0.633 0.002 0.001 0.005 <0.001 .
n 146 146 146 146 146 146 149
IR scores of Gal-1, -3, and -7 staining in different compartments were correlated with each other using Spearman’s
correlation analysis. cc = correlation coefficient, p = two-tailed significance, n = number of patients.
3. Discussion
According to our data, Gal-1 staining in cytoplasm and stroma share a negative prognostic
impact on overall survival in ovarian cancer. In accordance, in vitro experiments showed that
overexpression of Galectin-1 significantly increases migrative and invasive behavior of ovarian
cancer cells [19]. Furthermore, Gal-1 knockdown experiments in ovarian cancer cells displayed
a reduction in cell growth, migration, and invasion. Gal-1 interaction with H-Ras and activation of
the Raf/extracellular signal-regulated kinase (ERK) pathway as well as the downregulation of matrix
metalloproteinase-9 (MMP-9) and c-Jun could have been explored as possible mechanisms. Moreover,
Gal-1 overexpression could significantly decrease the sensitivities of ovarian cancer cells to cisplatin,
illustrating a possible explanation for decreased survival of ovarian cancer patients with increased
Gal-1 expression [14]. Thus, Gal-1 is a promising new target for ovarian cancer therapy. For this
purpose, several compounds targeting Gal-1 have been introduced [20]. OTX008, for instance, a new
compound binding non-covalently to Gal-1 on the side back face, was able to inhibit proliferation
and invasion of various cancer cells lines [21]. Anti-proliferative effects of OTX008 correlated with
Gal-1 expression across a large panel of cell lines. Moreover, OTX008 efficiently inhibited the growth of
ovarian cancer xenografts in vivo [22]. According to the results of a multivariate analysis, only Gal-1
stroma staining could serve as independent prognostic factor. Accumulation of Gal-1 in peritumoral
stroma has been described for various other tumor entities [23–25]. Some groups tried to investigate
the mechanisms responsible for this phenomenon. In situ hybridization experiments were able to
show that fibroblast cells, adjacent to malignant cells, express Gal-1 mRNA, illustrating a possible
explanation for peritumoral Gal-1 accumulation. Also, it was demonstrated that ovarian cancer cells
produce Gal-1 and release it to the medium. Furthermore, conditioned medium obtained from ovarian
carcinoma cells is able to induce increased gal-1 expression in fibroblast cells. Both experiments
suggest that primarily the ovarian cancer cells might be responsible for stromal Gal-1 expression [26].
Our exploration of the positive correlation between Gal-1 staining in peritumoral stroma and malignant
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cells is consistent with this hypothesis. However, it requires further investigations to explain cases
without Gal-1 expression in cancer cells but in the stroma or vice versa.
Several groups have suggested that higher Gal-3 expression is associated with reduced
progression-free survival in ovarian cancer [17,27]. However, in these studies, observation of Gal-3
expression was limited to the cytoplasm, while the prognostic value of nuclear Gal-3 staining has not
been further studied. We could not confirm a negative influence of cytoplasmic Gal-3 overexpression
on overall survival for our study panel. On the contrary, nuclear Gal-3 staining served as a positive
prognostic factor, although not independent of clinical and pathological parameters. Apparently, it
is the nuclear and not cytoplasmic Gal-3 expression that has a major influence on patients’ outcome.
In line with this, Gal-3 has been observed to play an important role in nuclear cell physiology, as it
is involved in the mechanisms of pre-mRNA-splicing or mRNA transport [28,29]. Furthermore, cell
culture experiments using human cervix adenocarcinoma HeLa-cells showed a delayed DNA damage
repair response activation and a decrease in the G2/M cell cycle checkpoint arrest in the absence of
Gal-3 [30]. A similar mechanism could be conceivable in ovarian cancer, predisposing cells for further
mutations in the absence of nuclear Gal-3. To our knowledge, reduced Gal-3 expression as an indicator
of poorer prognosis has only been observed in gastric cancer so far [31]. In cholangiocarcinoma,
Gal-3 expression was associated with a poorly-differentiated type, while in vitro experiments showed
significantly increased cell migration and invasion after suppression of Gal-3 expression [32]. However,
for ovarian cancer, in vitro experiments showed knockdown of Gal-3 inhibits migration and invasion
of cancer cells, while apoptosis and sensitivity to carboplatin increases [33]. Moreover, paclitaxel and
additional Gal-3 inhibitor treatment showed synergistic cytotoxic effects and increased apoptosis in
an on ovarian cancer cell line [34]. Since there are disagreements in previous research and our data is
neither consistent with previous studies on progression-free survival nor with recent results of in vitro
research, further investigation on the prognostic role of Gal-3 in ovarian cancer is definitely required.
As recently proposed by other groups, we were able to confirm Gal-7 as negative prognosticator
for overall survival in ovarian cancer in uni- and multivariate analysis. Further cell culture experiments
were able to prove that Gal-7 expression is induced by a mutant form of p53. Also, gal-7 was shown
to increase proliferation [16], invasiveness, and motility of ovarian cancer cells, while interacting
immunosuppressive by killing Jurkat T-cells and human peripheral T-cells [18]. All in all, these
investigations confirm Gal-7 as a new promising target for specific therapeutic option in epithelial
ovarian cancer. We observed various positive correlations between Gal-1, -3, and -7. This observation,
and the fact that Galectins share binding affinities and have similarities in protein structure, suggests
the assumption that Galectins might also share common functions in ovarian cancer molecular biology.
However, since this observation is rather descriptive, further investigations are required to explore the
biological characteristics and functions of different Galectins to determine the manner(s) in which they
are similar or different in specific regards to their role(s) in ovarian cancer.
4. Materials and Methods
4.1. Patients
Formalin-fixed, paraffin-embedded (FFPE) ovarian cancer samples from 156 female patients who
underwent surgery at the Department of Obstetrics and Gynecology, Ludwig-Maximilians- University
of Munich, Germany between 1990 and 2002 were analyzed in this study. Women diagnosed for
benign or for borderline tumors of the ovary were excluded and no patient had received neo-adjuvant
chemotherapy. Tumor grading (G1 (n = 38), G2 (n = 53), G3 (n = 53)), and histological characterization
(serous (n = 110), endometrioid (n = 21), clear cell (n = 12), mucinous (n = 13)) were performed by
a gynecological pathologist. Tumor staging was accomplished using FIGO classification (I (n = 35),
II (n = 10), III (n = 103), IV (n = 3)). TNM classification was performed according to UICC. Data on
the extension of the primary tumor was available in 155 cases (T1 (n = 40), T2 (n = 18), T3 (n = 93),
T4 (n = 4)), data on lymph node involvement was available in 95 cases (N0 (n = 43), N1 (n = 52) and
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data on the presence of distant metastasis was available in 9 cases (M0 (n = 3), M1 (n = 6). Clinical
data was retrieved from patients’ charts and follow up data was requested from the Munich Cancer
Registry. Patients’ age at surgery ranged between 31 and 88 years, with a median age of 62 ±12 years.
Mean overall survival was 3.2 ± 3.0 years and 104 deaths were observed in total. The mean follow up
time was 5.1 ± 4.8 years.
4.2. Immunochemistry
Resected ovarian cancer tissue samples were fixed in formalin and embedded in paraffin after
surgery. For histopathological investigations, sections were dewaxed in Xylol for 20 minutes and
immersed in 3% hydrogen peroxide (Merck, Darmstadt, Germany) to quench endogenous peroxidase.
Then slides were rehydrated in a descending series of alcohol (100%, 75%, and 50%), and cooked
for 5 minutes in sodium citrate buffer (0.1 mol/L citric acid/0.1 mol/L sodium citrate, pH 6.0)
in a pressure cooker to ensure epitope retrieval. Afterwards, slides were washed in distilled
water and phosphate-buffered saline (PBS), followed by a specific procedure for each Galectin
staining. In particular, for Galectin-1 (Gal-1) staining, slides were blocked using power block
(BioGenex, San Ramon, CA, USA) for 3 min at room temperature and incubated with Anti-Galectin 1
primary antibody (goat, polyclonal; R&D Systems, Minneapolis, MN, USA) at a final concentration
of 0.033 µg/mL in power block (BioGenex, San Ramon, CA, USA) for 16 h at 4 ◦C. Galectin-3
(Gal-3) staining was performed by blocking specimens with 1.5% horse serum (Vector Laboratories,
Burlingame, CA, USA) for 30 min at room temperature and incubating with Anti-Galectin 3 primary
antibody (mouse, monoclonal, Novocastra Reagents, Leica Biosystems, Wetzlar, Germany) at a final
concentration of 4.6 µg/mL in PBS for 16 h at 4 ◦C. For Galectin-7 (Gal-7) staining, specimens were
blocked with Blocking Solution (Reagent 1; ZytoChem Plus HRP Polymer System (Mouse/Rabbit);
Zytomed Systems GmbH, Berlin, Germany) for 5 minutes at room temperature. Slides were then
incubated with Anti-Gal-7 (rabbit, polyclonal; Abcam, Cambridge, UK) at a final concentration of
2.5 µg/mL in PBS for 16 h at 4 ◦C. Afterwards, for Gal-1 and -3 staining, slides were incubated with
isotype-matching anti-goat/mouse-IgG secondary antibody and avidin-biotin-peroxidase complex
both for 30 min at room temperature, according to ABC Vectastain kit (Vector Laboratories, Burlingame,
CA, USA). For Gal-7 staining, specimens were incubated in post-block reagent (Reagent 2) (Zytomed
Systems GmbH, Berlin, Germany) and HRP-Polymer (Reagent 3) (Zytomed Systems GmbH, Berlin,
Germany) for 30 min at room temperature, according to the manufacturer’s protocol (ZytoChem Plus
HRP Polymer System (Mouse/Rabbit). All slides were washed twice in PBS for 2 min after every
incubation step. For visualization reaction, every specimen was stained with 3,3′-diaminobenzidine
chromogen (DAB; Dako, Glostrup, Denmark), stopped after 30 s to 2 min with tap water, counterstained
in Mayer acidic hematoxylin, dehydrated in an ascending series of alcohol followed by xylol, and
covered with Consul Mount (Thermo Shandon, Pittsburgh, PA, USA). Tissue sections that had been
previously incubated with isotype-matched rabbit-/mouse-/goat- IgG (Dako, Hamburg, Germany)
instead of the primary antibody served as negative controls. For positive control, tissue slides of
placental tissue (Gal-1, -3) or breast cancer (Gal-7) were used. Primary antibodies were chosen due to
high expected staining specificities according to the results of positive control staining, description, and
example pictures on the manufacturer’s homepages. A semi-quantitative method (IR score; Remmele
score) was performed by two independent observers in consensus to obtain staining results. For this
purpose, the predominant staining intensity (0 = negative, 1 = low, 2 = moderate, and 3 = strong) and
the percentage of stained cells (0 = 0%, 1 = 1–10%, 2 = 11–50%, 3 = 51–80%, and 4 = 81–100% stained
cells) has to be multiplied, resulting in values from 0 to 12. Staining intensity was measured in the
cytoplasm and the nucleus of the cancer cells, and in the peritumoral stroma. Cut-off points for IR
scores were chosen specifically for each staining with regard to the distribution pattern of IR scores
in the collective. For Gal-1 staining in cytoplasm and nucleus of cancer cells, IRS = 0 was considered
as negative and an IRS ≥ 1 as positive. For stroma staining, Gal-1 groups of low expression (IRS < 5)
and high expression (IRS ≥ 5) were compared. For analysis of Gal-3 staining, negative cases with an
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IRS = 0 were compared to positive cases with an IRS ≥ 1. Gal-7 expression was grouped as negative
(IRS = 0), low (1 ≥ IRS ≥ 4), and high (IRS ≥ 6).
4.3. Statistical Analysis
Statistical data was obtained using SPSS 23.0 (v23, IBM, Armonk, NY, USA) statistic software.
Distribution of clinicopathological variables was tested with Chi-Square Statistics. Mann-Whitney
U-test was used to compare IR scores of Galectins between different clinical and pathological subgroups.
Correlations between immunochemical staining results were calculated using Spearman’s correlation
analysis. Kaplan-Meier curves and Log-rank test (Mantel-Cox) were used to compare survival times
between different groups. Data are presented with the mean ± standard deviation. Values of p < 0.05
were considered as significant.
4.4. Ethics Statement
All tissue samples used for this study were left-over material from the archives of LMU Munich,
Department Gynecology and Obstetrics, Ludwig-Maximilians-University, Munich, Germany, that had
initially been collected for histopathological diagnostics. All diagnostic procedures had already been
fully completed at the time the histopathological investigations for the current study were performed.
Patients’ data have been fully anonymized. The study was approved by the Ethics Committee of
LMU Munich. All experiments were performed according to the standards set in the declaration of
Helsinki 1975.
5. Conclusions
We were able to show that Galectin expression and its impact on overall survival of ovarian
cancer patients is strongly dependent of its localization, whether it is in the nucleus or cytoplasm of
tumor cells or the peritumoral stroma. We elaborated that Gal-1 tumor and stroma staining, and Gal-7
staining in the cytoplasm serves as a negative prognostic factor for overall survival in ovarian cancer,
while nuclear Gal-3 staining could serve as a positive prognostic factor. According to the results of a
multivariate analysis, Gal-1 stroma staining and Gal-7 staining are prognostic factors, independent of
clinical and pathological parameters.
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